Recommendations for Horizon Scanning, Topic Identification, Selection and Prioritisation for European Cooperation on Health Technology Assessment now available
The final report ‘Recommendations for Horizon Scanning, Topic Identification, Selection and Prioritisation for European Cooperation on Health Technology Assessment’ is now available. The draft recommendations were under consultation during the period July–September 2018. An overview and response to the feedback during the consultation is available, together with Endpoint Evaluations for both Pharmaceuticals and Other Technologies. […]
EUnetHTA Magazine – Winter 2020 – Now Available
We are pleased to publish the Winter 2020 issue of EUnetHTA Magazine, our quarterly update on HTA with input from network stakeholders. As always, we welcome your feedback so we can continue to improve how we can focus on developments in HTA. Happy reading! Click here for more.
PTJA05 – enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation
On 6 Dec 2019, Celgene officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for enasidenib. Since no CHMP opinion will be granted at this stage, EUnetHTA closed this Joint Assessment on 12 Dec 2019. The final Project Plan for the applied […]
EUnetHTA 2020 Forum
The EUnetHTA 2020 Forum was originally planned to be held on 2nd April at Zorginstituut Nederland (ZIN), the Dutch Health Care Institute, in Diemen near Amsterdam. However, due to the ongoing Covid-19 pandemic, the Forum had to be postponed. in light of this, we are, however, pleased to offer the accompanying Welcome Guide that was […]
EUnetHTA releases the second version of its methodological guideline “Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness”
The aim of this methodological guideline is to provide an up-to-date and transparent overview of the whole information retrieval process for Systematic reviews and HTAs on clinical effectiveness. In particular, the requirements presented in this methodological guideline aim to provide orientation for systematic searches on clinical effectiveness conducted within the framework of EUnetHTA. About this […]
Minutes from 2018 EUnetHTA-EFPIA Technical Meeting now available
The minutes from the EUnetHTA-EFPIA Technical Meeting, held on 11th December 2018 at the Haute Autorité de Santé in Paris, are now available for access. Participants included attendees from both EFPIA and EUnetHTA, as well as the EMA and DG SANTE. Topics presented and discussed included: Governance changes in EUnetHTA; Various developments and experiences from […]
EUnetHTA 2019 Forum – Registration Now Open!
We are pleased to announce that registration is now open for the EUnetHTA 2019 Forum, held this year at the West-Indisch Huis in Amsterdam, the Netherlands, on 11 April 2019. Consisting of EUnetHTA Consortium partners, stakeholder groups, and other organisations involved in the activities of EUnetHTA JA3, the Forum provides a focal point for the open […]
Livestreaming from Shaping Regulatory Science to 2025
Found livestream link HERE EUnetHTA’s SSO Giovanni Tafuri and ExB Chair Niklas Hedberg will participate in panel discussions at Shaping regulatory science to 2025. EMA is hosting the workshop on Wednesday, 24 October to gather insight from stakeholders on the key areas in human medicines to be covered in its ‘Regulatory Science Strategy to 2025’, a proposed new high-level plan […]
OTCA15 Irreversible electroporation in liver and pancreatic cancer project plan now available
The final project plan of the assessment on “Irreversible electroporation in liver and pancreatic cancer” and the comments provided by the external experts and the manufacturers are now available. OTCA15 Project Plan HERE OTCA15 External Expert and Manufacturer Comments HERE
OTCA17 Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH) Project Plan Now Available
The final project plan of the assessment on “Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH)” and the comments provided by the external experts and the manufacturers are now available. OTCA17 Project Plan HERE OTCA17 External Expert and Manufacturer Comments HERE
